AtriCure Inc. (NASDAQ:ATRC) Expected to Post Earnings of -$0.18 Per Share
Equities analysts expect AtriCure Inc. (NASDAQ:ATRC) to post ($0.18) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for AtriCure’s earnings, with the lowest EPS estimate coming in at ($0.20) and the highest estimate coming in at ($0.16). AtriCure posted earnings of ($0.19) per share during the same quarter last year, which would suggest a positive year over year growth rate of 5.3%. The company is scheduled to report its next earnings report after the market closes on Tuesday, July 30th.
According to Zacks, analysts expect that AtriCure will report full-year earnings of ($0.70) per share for the current financial year, with EPS estimates ranging from ($0.74) to ($0.65). For the next financial year, analysts anticipate that the business will post earnings of ($0.50) per share, with EPS estimates ranging from ($0.62) to ($0.42). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow AtriCure.
AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Thursday, April 25th. The medical device company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04. AtriCure had a negative return on equity of 14.35% and a negative net margin of 7.98%. The firm had revenue of $53.97 million for the quarter, compared to analyst estimates of $52.45 million. During the same period in the previous year, the company posted ($0.31) earnings per share. The company’s quarterly revenue was up 14.9% compared to the same quarter last year.
ATRC traded up $0.08 on Friday, hitting $30.78. 1,254 shares of the stock traded hands, compared to its average volume of 204,132. AtriCure has a 52 week low of $26.11 and a 52 week high of $36.49. The company has a quick ratio of 3.69, a current ratio of 4.37 and a debt-to-equity ratio of 0.19. The company has a market cap of $1.22 billion, a price-to-earnings ratio of -32.66 and a beta of 0.27. The business has a fifty day moving average of $30.26.
In other news, CEO Michael H. Carrel sold 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $32.00, for a total value of $800,000.00. Following the sale, the chief executive officer now directly owns 661,103 shares in the company, valued at approximately $21,155,296. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO M. Andrew Wade sold 9,850 shares of the company’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $30.00, for a total value of $295,500.00. Following the completion of the sale, the chief financial officer now owns 166,824 shares in the company, valued at $5,004,720. The disclosure for this sale can be found here. Over the last quarter, insiders sold 60,554 shares of company stock worth $1,866,620. Corporate insiders own 8.00% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in ATRC. Bell Rock Capital LLC acquired a new position in shares of AtriCure in the 1st quarter worth approximately $26,000. PRW Wealth Management LLC acquired a new position in shares of AtriCure in the 4th quarter worth approximately $61,000. Quantamental Technologies LLC acquired a new position in shares of AtriCure in the 1st quarter worth approximately $82,000. Great West Life Assurance Co. Can boosted its holdings in shares of AtriCure by 104.3% in the 4th quarter. Great West Life Assurance Co. Can now owns 4,400 shares of the medical device company’s stock worth $130,000 after acquiring an additional 2,246 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its holdings in shares of AtriCure by 121.2% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,331 shares of the medical device company’s stock worth $133,000 after acquiring an additional 2,373 shares in the last quarter. 89.34% of the stock is currently owned by institutional investors and hedge funds.
AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy.
Featured Article: Return on Investment (ROI) Defined, Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.